NCT06841952View on ClinicalTrials.gov

Study of Tretinoin Capsules in Combination With Azacitidine and Venetoclax in Treatment Naïve Participants With Acute Myeloid Leukemia

NANot yet recruitingINTERVENTIONAL

Enrollment

158

Participants

Timeline

Start Date

February 15, 2025

Primary Completion Date

December 15, 2028

Study Completion Date

December 15, 2030

Conditions

AML, Adult

Interventions

DRUG

ATRA+Venetoclax+Azacitidine

Participants will receive a standard dose of azacitidine (75mg/m²/day)，venetoclax (target dose, 400 mg)，ATRA 45mg/m²/day

DRUG

Chemotherapy drug

Participants will receive commercially available cytarabine (cytosine arabinoside) and anthracycline (daunorubicin).

Trial Locations (1)

Unknown

The First Affiliated Hospital of Soochow University, Suzhou

All Listed Sponsors

lead

The First Affiliated Hospital of Soochow University

OTHER

NCT06841952 - Study of Tretinoin Capsules in Combination With Azacitidine and Venetoclax in Treatment Naïve Participants With Acute Myeloid Leukemia | Biotech Hunter | Biotech Hunter